贝达药业：与晟斯生物达成战略合作

Core Viewpoint - Beida Pharmaceutical has entered into a strategic partnership with Shengsi Bio, focusing on collaboration in research, clinical trials, production, registration, and sales promotion [2] Group 1: Strategic Collaboration - Beida Pharmaceutical signed a Strategic Cooperation Framework Agreement with Shengsi Bio to provide support across various stages including R&D, clinical, production, registration, and sales [2] - Beida Pharmaceutical's wholly-owned subsidiary, Beida Medical Sales, has signed a Commercial Cooperation Agreement with Hangzhou Shengsi Bio to obtain exclusive general agency rights for FRSW117 in the Greater China region [2] Group 2: Product Information - FRSW117 is a long-acting recombinant factor VIII, classified as a Class 1 therapeutic biological product, which has recently completed Phase III clinical trials [2] - Currently, there are no domestically approved long-acting recombinant factor VIII products available in the market [2]